Together, our results show that expanding the application of PARP inhibitors beyond breast cancer with BRCA1 mutations (irrespective of BRCA1 status) and optimizing combinative treatment using PARP inhibitors with antimetastasis ruthenium-based chemotherapy could represent a new therapeutic approach for TNBC harboring wild-type BRCA1. Here, BRCA1 is linked to breast carcinoma.